Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
LETTER TO THE EDITOR
Year : 2012  |  Volume : 8  |  Issue : 3  |  Page : 460

Somatostatin analog and mTOR inhibitor treatment of Merkel cell tumor


Department of Clinical Oncology and Radiation Therapy, Charles University Hospital, Hradec Kralove, Czech Republic

Date of Web Publication17-Nov-2012

Correspondence Address:
Ladislav Slovacek
Department of Clinical Oncology and Radiation Therapy, Charles University Hospital, Hradec Kralove
Czech Republic
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.103536

Rights and Permissions

How to cite this article:
Slovacek L. Somatostatin analog and mTOR inhibitor treatment of Merkel cell tumor. J Can Res Ther 2012;8:460

How to cite this URL:
Slovacek L. Somatostatin analog and mTOR inhibitor treatment of Merkel cell tumor. J Can Res Ther [serial online] 2012 [cited 2019 Nov 12];8:460. Available from: http://www.cancerjournal.net/text.asp?2012/8/3/460/103536

Sir,

I read with great interest the article by author Fakiha et al.[1]devoted to the issue of remission of Merkel cell tumor after somatostatin analog treatment. I would like this case added to my own experience with somatostatin analog and mTOR inhibitor treatment of Merkel cell tumor in a 70-year-old female patient. The patient underwent radical right elbow surgery, followed by adjuvant radiotherapy to a total dose of 54 Gy in 27 fractions in January 2008. After three months, there was tumor progression -new bearings on the right arm. Palliative chemotherapy based on cisplatin and etoposide was indicated. Patient received five cycles of chemotherapy and we achieved a regression of the disease. Another local disease progression on the right arm occurred at intervals of approximately nine months, we indicated re-irradiation of right arm and then five cycles of palliative chemotherapy based on cisplatin and etoposide in reduced doses of both chemotherapy by 25% due to hematological toxicity (pancytopenia) was given in addition, which led to stable disease. About three months later, there was a significant local tumor progression not only on the right arm, but also on the right side of the neck and chest wall. Due to exhaust the possibilities of cancer therapy, the patient was considered for a biological treatment. Somatostatin analog treatment (lanreotide 120 mg intramuscularly at intervals of two weeks) was indicated because of the positive octreoscan. There was clinically significant progression in the number of active sites on the right upper extremity and right chest wall after three applications of lanreotide. It was therefore resorted to a combination lanreotide with mTOR inhibitor (everolimus at a dose of 10 mg daily). After one month of combined biological therapy, there was another tumor progression. Cancer treatment was finally stopped.The patient died at an interval of one month from the completion of cancer treatment.

 
 > References Top

1.Fakiha M, Letertre P, Vuillez JP, Lebeau J. Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther 2010;6:382-4.  Back to cited text no. 1
[PUBMED]    



This article has been cited by
1 Cisplatin/etoposide
Reactions Weekly. 2014; 1490(1): 14
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article
>References

 Article Access Statistics
    Viewed1503    
    Printed58    
    Emailed0    
    PDF Downloaded130    
    Comments [Add]    
    Cited by others 1    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]